GEN Exclusives

More »

GEN News Highlights

More »
Dec 16, 2010

GSK to Use BioClinica Tool to Manage Clinical Trials

  • GlaxoSmithKline (GSK) entered into a multiyear agreement with BioClinica to deploy the latter’s Trident IWR (interactive web response) system across its Phase I–IV trials. Trident IWR’s design provides clinical operation personnel with the ability to set up, monitor, and maintain randomization and supplies for their clinical trials.

    Trident IWR delivers study setup without the need for programming while simultaneously providing IVR system phone support through the same simplified configuration process. It was designed by the team that reportedly created the world’s first parameter-driven IWR for a top five global pharmaceutical company.

    That software, designed by Tourtellotte Solutions, a company that BioClinica acquired in September 2009, is currently being used in more than 150 active clinical trials, and has been used in more than 300 trials since its inception, according to BioClinica.

    “GSK had a requirement for a new solution to enable internal staff to configure and manage highly complex IWR clinical studies, and we are pleased GSK chose Trident,” notes Mark Weinstein, CEO of BioClinica. “We look forward to supporting GSK so that they can successfully deploy and utilize our software in their upcoming studies.”

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »